CHAMPIONS ONCOLOGY, INC. Revenue from Contract with Customer, Including Assessed Tax
CHAMPIONS ONCOLOGY, INC. (CSBR) reported Revenue from Contract with Customer, Including Assessed Tax of $7.63 million for the 3-month period ending 2019-10-31, per its 10-Q filed 2019-12-16.
Discontinued › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax · last filed 2019-12-16
- CHAMPIONS ONCOLOGY, INC. revenue from contract with customer, including assessed tax for the quarter ending 2019-10-31 was $7.63M, a 13.92% increase year-over-year.
- CHAMPIONS ONCOLOGY, INC. revenue from contract with customer, including assessed tax for the quarter ending 2019-07-31 was $6.74M, a 8.22% increase year-over-year.
- CHAMPIONS ONCOLOGY, INC. revenue from contract with customer, including assessed tax for the quarter ending 2019-01-31 was $6.43M, a 26.52% increase year-over-year.
- CHAMPIONS ONCOLOGY, INC. revenue from contract with customer, including assessed tax for the quarter ending 2018-10-31 was $6.69M, a 28.64% increase year-over-year.
| Period end | Revenue from Contract with Customer, Including Assessed Tax 3 month | Revenue from Contract with Customer, Including Assessed Tax 6 month | Revenue from Contract with Customer, Including Assessed Tax 9 month |
|---|---|---|---|
| 2019-10-31 | $7.63M 10-Q · filed 2019-12-16 | $14.36M 10-Q · filed 2019-12-16 | |
| 2019-07-31 | $6.74M 10-Q · filed 2019-09-16 | ||
| 2019-01-31 | $6.43M 10-Q · filed 2019-03-18 | $13.12M derived: sum of 2 quarters · filed 2019-12-16 | $19.35M 10-Q · filed 2019-03-18 |
| 2018-10-31 | $6.69M 10-Q · filed 2019-12-16 | $12.92M 10-Q · filed 2019-12-16 | |
| 2018-07-31 | $6.22M 10-Q · filed 2019-09-16 | ||
| 2018-01-31 | $5.08M 10-Q · filed 2019-03-18 | $10.29M derived: sum of 2 quarters · filed 2019-03-18 | $15.32M 10-Q · filed 2019-03-18 |
| 2017-10-31 | $5.20M 10-Q · filed 2018-12-17 | $10.24M 10-Q · filed 2018-12-17 | |
| 2017-07-31 | $5.03M 10-Q · filed 2018-09-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |